Latest Financial Results
16 April 2025 – 1 mins read
LinkedIn
Facebook
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission to EMA2 for pediatric low-grade glioma.Confirmation of full-year 2025 financial guidance. PARIS,…
13 February 2025 – 1 mins read
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
PARIS, FRANCE, 13 February 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the full year 2024.
24 April 2024 – 1 mins read
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
Filter
Period
Filter by
recent search
Showing: 1 – 05 of 29 Financial Results
22 April 2020
LinkedIn
Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact
Paris (France), 22 April 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its sales for the first quarter of 2020.
13 February 2020
LinkedIn
Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook
Aymeric Le Chatelier, Chief Executive Officer and Chief Financial Officer of Ipsen, stated: “2019 was another excellent year of operating performance for Ipsen with continued double-digit top-line growth and core operating margin expansion. Despite the recent palovarotene setback, the fundamentals of…
24 October 2019
LinkedIn
Ipsen delivers strong double-digit sales growth for the third quarter of 2019 and confirms full year 2019 guidance
Unaudited IFRS consolidated sales
25 July 2019
LinkedIn
Ipsen delivers strong results for the first half of 2019 with robust double-digit sales growth and improved Core Operating margin and upgrades its guidance for full year 2019
Extract of audited consolidated results for H1 2019 and 2018
24 April 2019
LinkedIn
Ipsen reports strong double-digit sales growth in First Quarter 2019 and confirms Full Year 2019 financial targets
First quarter 2019 unaudited IFRS consolidated sales
Your dedicated contacts
-
Khalid Deojee
Senior Manager, Investor Relations
